Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study assessed the utility of plasma fragments of propeptides of type III (PRO-C3), V (PRO-C5), and VI (PRO-C6) procollagen for the detection of liver fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Patients with T2DM (n = 191) underwent an oral glucose tolerance test, a liver 1H-MRS, and a liver biopsy when indicated. PRO-C3, PRO-C5, and PRO-C6 were blindly assessed. RESULTS: PRO-C3 performed well for the diagnosis of moderate-to-advanced (area under the receiver operating characteristic curve [AUROC] 0.81 [95% CI 0.74–0.88]) and advanced (AUROC 0.88 [0.80–0.95]) fibrosis in T2DM patients. Its performance was similar to that of AST to platelet ratio index (APRI) (AUROC 0.83 and 0.87, respectively) and Fibrosis-4 (FIB-4) (AUROCs 0.83 and 0.86, respectively) scores. Use of PRO-C5 and PRO-C6 did not improve the accuracy to detect liver fibrosis. After 18 months, PRO-C3 changes were associated with changes in fibrosis stages. CONCLUSIONS: PRO-C3 performed well for the detection of fibrosis in T2DM patients and showed promising results for prediction of histological changes in fibrosis stage with treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo37.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [37]
Citations
Cites
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Self-citationManagement of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Self-citationBril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312 · cited 1×
“Details and results from those randomized controlled trials have previously been published (13,14).”
BackgroundSelf-citationDaniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273 · cited 6×
“Only recently have efforts focused in a population exclusively of patients with T2DM, but results have been mixed and not widely embraced by health care providers (5,6).”
BackgroundSelf-citationBril, F., Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Freckleton, M., Chintapalli, K., Hardies, J., Lai, S., Solano, F., Tio, F., et al. (2015) · Liver International · doi:10.1111/liv.12840 · Cited by 237 · cited 1×
“Study Design All patients underwent proton MRS ((1)HMRS) to measure intrahepatic triglyceride content as previously reported (15), a 2-h OGTT (with blood collection every 30 min), and a percutaneous liver biopsy if patients had NAFLD.”
MethodSelf-citation(2013) · Europe PMC (PubMed Central) · Cited by 214
Self-citationBazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
Adams, L. A., George, J., Bugianesi, E., Rossi, E., De Boer, W. B., van der Poorten, D., Ching, H. L. I., Bulsara, M., & Jeffrey, G. P. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06774.x · Cited by 172
Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K. (2015) · Liver International · doi:10.1111/liv.12700 · Cited by 144
Self-citation
Cited by
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationHartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
“direct marker of fibrogenesis and its use as a biomarker in those with type 2 diabetes can aid the identification of patients with moderately advanced and advanced fibrosis (34,35).”
BackgroundSanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo 37 .”
BackgroundBril, F., McPhaul, M. J., Caulfield, M. P., Clark, V. C., Soldevilla-Pico, C., Firpi-Morell, R. J., Lai, J., Shiffman, D., Rowland, C. M., & Cusi, K. (2020) · Diabetes Care · doi:10.2337/dc19-1071 · Cited by 179
“Patients included in this analysis have been previously reported on in studies that focused on assessing the performance of plasma fragments of propeptide of type III procollagen (PRO-C3) (22), the FibroMax test (20), and OWLiver test (19) in patients with T2DM.”
BackgroundSelf-citation
Metadata
- Authors
- Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Nordic Bioscience (Denmark) (DK)
- Corresponding author
- Cusi, Kenneth
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-05-21
- Volume
- 42
- Issue
- 7
- Pages
- 1348-1351
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2946261704
- Cited by
- 52
- References
- 17
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 10 · 2023: 9 · 2022: 7 · 2021: 11 · 2020: 8 · 2019: 2
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liver fibrosis, type 2 diabetes, PRO-C3, non-invasive fibrosis markers, APRI, FIB-4, fibrosis staging, liver biopsy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Biopsy, Diabetes Mellitus, Type 2, Female, Humans, Liver Cirrhosis, Longitudinal Studies, Male, Middle Aged, Magnetic Resonance Spectroscopy, Peptide Fragments, Platelet Count, Predictive Value of Tests, Procollagen, Sensitivity and Specificity, Biomarkers, Collagen Type III, Collagen Type V, Collagen Type VI, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc18-2578
- The paper
- Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019). Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc18-2578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.